A prescription for the US FDA for the regulation of health misinformation

被引：3
作者：
Kadakia, Kushal T. [1 ]
Beckman, Adam L. [1 ,2 ]
Krumholz, Harlan M. [3 ,4 ,5 ]
机构：
[1] Harvard Med Sch, Boston, MA USA
[2] Harvard Sch Business, Boston, MA USA
[3] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06510 USA
[4] Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT 06510 USA
[5] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA
来源：
NATURE MEDICINE | 2023年 / 29卷 / 03期
关键词：
D O I：
10.1038/s41591-022-02172-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The US Food and Drug Administration should address health misinformation through existing and new regulatory approaches, including modernizing product labeling, investing in infodemic surveillance and addressing the roles of the internet and social media.
引用
收藏
页码：525 / 527
页数：3
相关论文
共 20 条
  • [1] Aboulenein, 2022, REUTERS 0217
  • [2] Adams S. H., 2013, GREAT AM FRAUD
  • [3] [Anonymous], 1982, NEW YORK TIMES 0203
  • [4] [Anonymous], 2007, Preventing Medication Errors: Quality Chasm Series
  • [5] [Anonymous], Why You Should Not Use Ivermectin to Treat or Prevent COVID-19
  • [6] [Anonymous], FDA ANNOUCES NEW PRE
  • [7] [Anonymous], 2020, Managing the COVID-19 infodemic: promoting healthy behaviours and mitigating the harm from misinformation and disinformation
  • [8] [Anonymous], FDA CAUTIONS USE HYD
  • [9] [Anonymous], 2021, Health Misinformation Act of 2021, S.2448
  • [10] [Anonymous], 2014, INTERNET SOCIAL MEDI
12